A PYMNTS Company

US: Intuniv ‘inappropriately’ hired its experts says Teva

By  |  April 30, 2019

Teva Pharmaceutical Industries is seeking to disqualify two expert witnesses hired by plaintiffs who are accusing one of the drugmaker’s units of illegally delaying the release of a generic version of the ADHD drug Intuniv, saying they previously testified for the company.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Teva in a motion filed on Friday in Boston federal court said both professors had served as expert witnesses for Teva in earlier patent litigation involving Intuniv, and generic drugmaker Actavis, which Teva acquired from Allergan in 2016.

    Both Teva and Actavis had been seeking to produce generic versions of Intuniv and were challenging the validity of patents brand-name drugmaker Shire held on the medication.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.